CARDIFF ONCOLOGY, INC. Net Income (Loss) Available to Common Stockholders, Diluted
CARDIFF ONCOLOGY, INC. (CRDF) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$6.76 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2021-08-05
- CARDIFF ONCOLOGY, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was -$6.76M.
- CARDIFF ONCOLOGY, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-03-31 was -$5.18M.
- CARDIFF ONCOLOGY, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2020-09-30 was -$4.50M.
- CARDIFF ONCOLOGY, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2020-06-30 was -$7.40M.
- CARDIFF ONCOLOGY, INC. net income (loss) available to common stockholders, diluted for fiscal 2019 was -$16.71M.
- CARDIFF ONCOLOGY, INC. net income (loss) available to common stockholders, diluted for fiscal 2018 was -$19.25M.
- CARDIFF ONCOLOGY, INC. net income (loss) available to common stockholders, diluted for fiscal 2017 was -$24.93M.
- CARDIFF ONCOLOGY, INC. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$41.55M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2021-06-30 | -$6.76M 10-Q · filed 2021-08-05 | -$11.95M 10-Q · filed 2021-08-05 | ||||
| 2021-03-31 | -$5.18M 10-Q · filed 2021-05-06 | |||||
| 2020-09-30 | -$4.50M 10-Q · filed 2020-11-05 | -$11.90M derived: sum of 2 quarters · filed 2021-08-05 | -$15.99M 10-Q · filed 2020-11-05 | -$20.24M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-06-30 | -$7.40M 10-Q · filed 2021-08-05 | -$7.40M 10-Q · filed 2020-08-11 | -$11.49M 10-Q · filed 2021-08-05 | -$11.49M 10-Q · filed 2020-08-11 | -$15.74M derived: sum of 3 quarters · filed 2021-08-05 | -$19.89M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$4.09M 10-Q · filed 2021-05-06 | -$4.09M 10-Q · filed 2020-05-07 | -$8.34M derived: sum of 2 quarters · filed 2021-05-06 | -$12.49M derived: sum of 3 quarters · filed 2021-05-06 | -$16.62M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | -$4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$8.40M derived: sum of 2 quarters · filed 2020-11-05 | -$12.53M derived: sum of 3 quarters · filed 2020-11-05 | -$16.71M 10-K · filed 2020-02-27 | ||
| 2019-09-30 | -$4.15M 10-Q · filed 2020-11-05 | -$8.28M derived: sum of 2 quarters · filed 2020-11-05 | -$12.46M 10-Q · filed 2020-11-05 | -$16.62M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | -$4.13M 10-Q · filed 2020-08-11 | -$8.31M 10-Q · filed 2020-08-11 | -$12.48M derived: sum of 3 quarters · filed 2020-08-11 | -$16.25M derived: sum of 4 quarters · filed 2020-08-11 | ||
| 2019-03-31 | -$4.18M 10-Q · filed 2020-05-07 | -$8.34M derived: sum of 2 quarters · filed 2020-05-07 | -$12.12M derived: sum of 3 quarters · filed 2020-05-07 | -$18.64M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | -$4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$7.94M derived: sum of 2 quarters · filed 2020-02-27 | -$14.46M derived: sum of 3 quarters · filed 2020-02-27 | -$19.25M 10-K · filed 2020-02-27 | ||
| 2018-09-30 | -$3.78M 10-Q · filed 2019-11-07 | -$10.30M derived: sum of 2 quarters · filed 2019-11-07 | -$15.09M 10-Q · filed 2019-11-07 | -$17.67M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | -$6.52M 10-Q · filed 2019-08-08 | -$11.31M 10-Q · filed 2019-08-08 | -$13.89M derived: sum of 3 quarters · filed 2019-08-08 | -$18.19M derived: sum of 4 quarters · filed 2019-08-08 | ||
| 2018-03-31 | -$4.79M 10-Q · filed 2019-05-07 | -$7.37M derived: sum of 2 quarters · filed 2019-05-07 | -$11.67M derived: sum of 3 quarters · filed 2019-05-07 | -$19.72M derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2017-12-31 | -$2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | -$6.87M derived: sum of 2 quarters · filed 2019-03-06 | -$14.93M derived: sum of 3 quarters · filed 2019-03-06 | -$24.93M 10-K · filed 2019-03-06 | ||
| 2017-09-30 | -$4.30M 10-Q · filed 2018-11-07 | -$12.35M derived: sum of 2 quarters · filed 2018-11-07 | -$22.36M 10-Q · filed 2018-11-07 | -$32.70M derived: sum of 4 quarters · filed 2018-11-07 | ||
| 2017-06-30 | -$8.05M 10-Q · filed 2018-08-03 | -$18.06M 10-Q · filed 2018-08-03 | -$28.40M derived: sum of 3 quarters · filed 2018-08-03 | -$38.60M derived: sum of 4 quarters · filed 2018-08-03 | ||
| 2017-03-31 | -$10.01M 10-Q · filed 2018-05-08 | -$20.35M derived: sum of 2 quarters · filed 2018-05-08 | -$30.54M derived: sum of 3 quarters · filed 2018-05-08 | -$40.75M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2016-12-31 | -$10.34M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$20.54M derived: sum of 2 quarters · filed 2018-02-26 | -$30.75M derived: sum of 3 quarters · filed 2018-02-26 | -$41.55M 10-K · filed 2018-02-26 | ||
| 2016-09-30 | -$10.20M 10-Q · filed 2017-11-09 | -$20.41M derived: sum of 2 quarters · filed 2017-11-09 | -$31.21M 10-Q · filed 2017-11-09 | -$38.97M derived: sum of 4 quarters · filed 2017-11-09 | ||
| 2016-06-30 | -$10.21M 10-Q · filed 2017-08-09 | -$21.01M 10-Q · filed 2017-08-09 | -$28.78M derived: sum of 3 quarters · filed 2017-08-09 | -$35.54M derived: sum of 4 quarters · filed 2017-08-09 | ||
| 2016-03-31 | -$10.80M 10-Q · filed 2017-05-10 | -$18.57M derived: sum of 2 quarters · filed 2017-05-10 | -$25.33M derived: sum of 3 quarters · filed 2017-05-10 | -$35.51M derived: sum of 4 quarters · filed 2017-05-10 | ||
| 2015-12-31 | -$7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$14.52M derived: sum of 2 quarters · filed 2017-03-15 | -$24.71M derived: sum of 3 quarters · filed 2017-03-15 | -$31.89M 10-K · filed 2017-03-15 | ||
| 2015-09-30 | -$6.76M 10-Q · filed 2016-11-09 | -$16.95M derived: sum of 2 quarters · filed 2016-11-09 | -$24.13M 10-Q · filed 2016-11-09 | -$29.02M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-06-30 | -$10.19M 10-Q · filed 2016-08-04 | -$17.37M 10-Q · filed 2016-08-04 | -$22.26M derived: sum of 3 quarters · filed 2017-03-15 | -$27.64M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-03-31 | -$7.18M 10-Q · filed 2016-05-10 | -$12.08M derived: sum of 2 quarters · filed 2017-03-15 | -$17.46M derived: sum of 3 quarters · filed 2017-03-15 | -$20.75M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2014-12-31 | -$4.89M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$10.28M derived: sum of 2 quarters · filed 2017-03-15 | -$13.57M derived: sum of 3 quarters · filed 2017-03-15 | -$16.77M 10-K · filed 2017-03-15 | ||
| 2014-09-30 | -$5.38M 10-Q · filed 2015-11-09 | -$8.68M derived: sum of 2 quarters · filed 2015-11-09 | -$11.88M 10-Q · filed 2015-11-09 | |||
| 2014-06-30 | -$3.30M 10-Q · filed 2015-08-10 | -$6.49M 10-Q · filed 2015-08-10 | ||||
| 2013-12-31 | -$11.84M 10-K · filed 2016-03-10 | |||||
| 2012-12-31 | -$11.60M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |